Product Name: EphA3 (776-782) pY779
Product Number: PE-04AGN65
Size: 200 µg      Price:11.00
1 mg      $US21.00
5 mg      58.00
Peptide Name: EphA3 (776-782) pY779

Product Use: Services as a blocking peptide for use with the EphA3-pY779 rabbit polyclonal antibody (Cat. No.: AB-PK608) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. Y779 phosphorylation stimulates phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: EAA-pY-TTR

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1065.03 Da

Peptide Purity Percent after Synthesis and Purification: >50

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: EphA3 - pY779 phosphosite-specific antibody (Cat. No.: AB-PK608)

Scientific Background: EphA3 is a protein-tyrosine kinase of the TK group and Eph family. It is a receptor kinase that binds ephrin ligands to induce contact signalling. It is activated by binding ephrin-A1, A2, A3, A4 or A5. Phosphorylation of Y596, Y602 and Y779 increases phosphotransferase activity and interaction with Crk. Upregulation of EphA3 is common in lung cancer and melanomas. Its mutation pattern in human tumours is very characteristic of a tumour suppressor protein.This pathway can regulate cell adhesion, migration, and movement. EphA3 function is inhibited and EFNA5 binding interrupted with the V133E, and F152L mutations. EphA3 is linked to Pleomorphic Rhabdomyosarcoma, which is a rare disease which is related to colorectal cancer, and can also affect the uterus, heart, and skeletal muscle tissues.